It was found that 26-week liraglutide reduced serum concentrations of hepatic ALT versus placebo (-8.20 vs. -5.01 IU/L; p = 0.03) in T2DM patients, the effects of which were thought to be mediated by its action on improved glycemic control and weight loss [25]. This evidence concerns the gene GPT and type 2 diabetes mellitus.